How do we work?
In-silico methods, together with high-performance computing infrastructures, the increasing availability of patient-specific data and big data analysis based on artificial intelligence, has the potential to bring clinical trials to the 21st century, leveraging standardised and trustworthy computational approaches. Three cardiac use cases will demonstrate in-silico trials effectiveness, along with the required verification & validation processes and certification support of the medical device or medicine. An unified web platform will enable to test the safety and efficacy of drugs and devices.
SimCardioTest will thus develop a standardised and secure cloud-based platform where in-silico trials will run seamlessly.
Three cardiac use cases to demonstrate our effectiveness
Pacing devices and leads
Includes modelisaltion of the navigation of these devices so as to improve the mechanical design of pacing leads, and understand the fatigue of these devices.
Left atrial appendage occluder (LAAO)
Includes the simulation of the blood flow and the device dedicated, to improve patient selection, optimize device settings and predict treatment response.
Drugs, efficacy and toxicity
Includes the development of the detailed models of the cardiac cell and, at the organ level, the measure the impact of different dosage of drugs depending specifically on the patient characteristics.
Video @Inria: details on the use cases studied within SimCardioTest
Pacing devices and leads
Includes modelisaltion of the navigation of these devices so as to improve the mechanical design of pacing leads, and understand the fatigue of these devices.
Left atrial appendage occluder (LAAO)
Includes the simulation of the blood flow and the device dedicated, so as to improve patient selection, optimize device settings and predict treatment response.
Drugs, efficacy and toxicity
Includes the development of the detailed models of the cardiac cell and, at the organ level, the measure the impact of different dosage of drugs depending specifically on the patient characteristics.
We validate and exploit our results
Furthermore, SimCardioTest will be conducted closely with the regulatory institutions as the results of the simulations can support the certification process. These simulations will be thoroughly verified, as well as the quantification of uncertainty within the predictions from in-silico simulations.
Finally, the exploitation potential of SimCardiotest outcomes on targeted EU and US markets will be assessed and the market sectors involved in the potential business opportunities for the system developed will be analysed. A competitive analysis will be carried out, as well as the analysis of potential customers and model of use. In 2022 an exploitation workshop with a group of stakeholders will present the outcomes of the preliminary market assessments and facilitate early discussion on exploitation scenarios.
Please contact us if you are interested in participating.
